ELTD1 Promotes Gastric Cancer Cell Proliferation, Invasion and Epithelial–Mesenchymal Transition Through MAPK/ERK Signaling by Regulating CSK

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-5
   PubMed Web of Science ®Google Scholar
• Addeo M, Di Paola G, Verma HK, et al. Gastric cancer stem cells: a glimpse on metabolic reprogramming. Front Oncol. 2021;11:698394. doi:10.3389/fonc.2021.698394
   PubMed Web of Science ®Google Scholar
• Kontomanolis EN, Koutras A, Syllaios A, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40(11):6009–6015. doi:10.21873/anticanres.14622
   PubMed Web of Science ®Google Scholar
• Verma HK, Falco G, Bhaskar LV. Molecular signaling pathways involved in gastric cancer chemoresistance. Theranos Approach Gastric Colon Cancer. 2021;4:117–134. doi:10.1155/2021/5519720
   Web of Science ®Google Scholar
• Nechiporuk T, Urness LD, Keating MT. ETL, a novel seven-transmembrane receptor that is developmentally regulated in the heart. ETL is a member of the secretin family and belongs to the epidermal growth factor-seven-transmembrane subfamily. J Biol Chem. 2001;276(6):4150–4157. doi:10.1074/jbc.M004814200
   PubMed Web of Science ®Google Scholar
• Favara DM, Banham AH, Harris AL. A review of ELTD1, a pro-angiogenic adhesion GPCR. Biochem Soc Trans. 2014;42(6):1658–1664. doi:10.1042/BST20140216
   PubMed Web of Science ®Google Scholar
• Masiero M, Simoes FC, Han HD, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013;24(2):229–241. doi:10.1016/j.ccr.2013.06.004
   PubMed Web of Science ®Google Scholar
• Favara DM, Zois CE, Haider S, et al. ADGRL4/ELTD1 silencing in endothelial cells induces ACLY and SLC25A1 and alters the cellular metabolic profile. Metabolites. 2019;9(12):287. doi:10.3390/metabo9120287
   PubMed Web of Science ®Google Scholar
• Xiao J, Jiang H, Zhang R, et al. Augmented cardiac hypertrophy in response to pressure overload in mice lacking ELTD1. PLoS One. 2012;7(5):e35779. doi:10.1371/journal.pone.0035779
   PubMed Web of Science ®Google Scholar
• Ziegler J, Pody R, Coutinho DSP, et al. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro Oncol. 2017;19(2):175–185. doi:10.1093/neuonc/now147
   PubMed Web of Science ®Google Scholar
• Kan A, Le Y, Zhang YF, et al. ELTD1 function in hepatocellular carcinoma is carcinoma-associated fibroblast-dependent. J Cancer. 2018;9(14):2415–2427. doi:10.7150/jca.24406
   PubMed Web of Science ®Google Scholar
• Li J, Shen J, Wang Z, et al. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1alpha signaling axis. Sci Rep. 2019;9(1):13904. doi:10.1038/s41598-019-50375-x
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–226. doi:10.1016/j.tcb.2018.12.001
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi:10.1038/nrm3758
   PubMed Web of Science ®Google Scholar
• Yang M, Huang CZ. Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. World J Gastroenterol. 2015;21(41):11673–11679. doi:10.3748/wjg.v21.i41.11673
   PubMed Web of Science ®Google Scholar
• Kazi JU, Vaapil M, Agarwal S, et al. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal. 2013;25(9):1852–1860. doi:10.1016/j.cellsig.2013.05.016
   PubMed Web of Science ®Google Scholar
• Gu J, Nada S, Okada M, et al. Csk regulates integrin-mediated signals: involvement of differential activation of ERK and Akt. Biochem Biophys Res Commun. 2003;303(3):973–977. doi:10.1016/s0006-291x(03)00468-6
   PubMed Web of Science ®Google Scholar
• Masaki T, Okada M, Tokuda M, et al. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology. 1999;29(2):379–384. doi:10.1002/hep.510290239
   PubMed Web of Science ®Google Scholar
• Liang F, Liang J, Wang WQ, et al. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282(8):5413–5419. doi:10.1074/jbc.M608940200
   PubMed Web of Science ®Google Scholar
• Rengifo-Cam W, Konishi A, Morishita N, et al. Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis. Oncogene. 2004;23(1):289–297. doi:10.1038/sj.onc.1207041
   PubMed Web of Science ®Google Scholar
• Sirvent A, Benistant C, Pannequin J, et al. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene. 2010;29(9):1303–1315. doi:10.1038/onc.2009.450
   PubMed Web of Science ®Google Scholar
• Kumar S, Lu B, Davra V, et al. Crk tyrosine phosphorylation regulates PDGF-BB-inducible Src activation and breast tumorigenicity and metastasis. Mol Cancer Res. 2018;16(1):173–183. doi:10.1158/1541-7786.MCR-17-0242
   PubMed Web of Science ®Google Scholar
• Guihurt SJ, Burgos-Tirado N, Lafontaine DD, et al. Adhesion G protein-coupled receptor, ELTD1, is a potential therapeutic target for retinoblastoma migration and invasion. BMC Cancer. 2021;21(1):53. doi:10.1186/s12885-020-07768-3
   PubMed Web of Science ®Google Scholar
• Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395–412. doi:10.1146/annurev-pathol-020117-043854
   PubMed Web of Science ®Google Scholar
• Huang L, Wu RL, Xu AM. Epithelial-mesenchymal transition in gastric cancer. Am J Transl Res. 2015;7(11):2141–2158.
   PubMed Web of Science ®Google Scholar
• Sevastre AS, Buzatu IM, Baloi C, et al. ELTD1-an emerging silent actor in cancer drama play. Int J Mol Sci. 2021;22(10):5151. doi:10.3390/ijms22105151
   PubMed Web of Science ®Google Scholar
• Serban F, Artene SA, Georgescu AM, et al. Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker. Onco Targets Ther. 2015;8:3767–3774. doi:10.2147/OTT.S93843
   PubMed Web of Science ®Google Scholar
• Zalles M, Smith N, Ziegler J, et al. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model. J Cell Mol Med. 2020;24(2):1738–1749. doi:10.1111/jcmm.14867
   PubMed Web of Science ®Google Scholar
• Zalles M, Smith N, Saunders D, et al. Assessment of an scFv antibody fragment against ELTD1 in a G55 glioblastoma xenograft model. Transl Oncol. 2020;13(3):100737. doi:10.1016/j.tranon.2019.12.009
   PubMed Web of Science ®Google Scholar
• Niinivirta M, Georganaki M, Enblad G, et al. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib. BMC Cancer. 2020;20(1):339. doi:10.1186/s12885-020-06770-z
   PubMed Web of Science ®Google Scholar
• Xiao T, Li W, Wang X, et al. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc Natl Acad Sci USA. 2018;115(31):7869–7878. doi:10.1073/pnas.1722617115
   PubMed Web of Science ®Google Scholar